| Aspirin/Dipyridamole |
Capsule |
I (Basket) |
100 |
0.01 N HCl for first hour, 0.1 M Phosphate Buffer, pH 5.5, thereafter |
0-1 hrs: 900 mL. 900 mL thereafter |
Acid: 10, 20, 30, 45 and 60 min; Buffer:1, 2, 5, and 7 hours |
2007/10/09 |
| Aspirin/Hydrocodone Bitartrate |
Tablet |
II (Paddle) |
75 |
Acetate Buffer, pH 4.5 |
900 |
10, 20, 30, 45, 60 and 90 |
2004/01/15 |
| Aspirin/Meprobamate |
Tablet |
|
|
Develop a dissolution method |
|
|
2023/09/15 |
| Aspirin/Methocarbamol |
Tablet |
|
|
Develop a dissolution method |
|
|
2023/09/15 |
| Aspirin/Oxycodone HCl |
Tablet |
|
|
Refer to USP |
|
|
2010/01/15 |
| Atazanavir Sulfate |
Capsule |
II (Paddle) |
50 |
0.025 N HCl |
1000 |
10, 20, 30 and 45 |
2006/01/20 |
| Atazanavir Sulfate/ Cobicistat |
Tablet |
II (Paddle) |
75 |
0.05 M Citrate Buffer (pH 2.8) |
1000 |
Atazanavir: 10, 15, 20, 30 and 45; Cobicistat: 5, 10, 15, 20 and 30 |
2015/12/24 |
| Atenolol |
Tablet |
|
|
Refer to FDA's Dissolution Guidance, 2018 |
|
|
2020/07/02 |
| Atenolol/Chlorthalidone |
Tablet |
|
|
Refer to USP |
|
|
2014/02/14 |
| Atogepant |
Tablet |
|
|
Refer to FDA's Dissolution Guidance, 2018 |
|
|
2023/05/18 |
| Atomoxetine HCl |
Capsule |
|
|
Refer to FDA's Dissolution Guidance, 2018 |
|
|
2020/07/02 |
| Atorvastatin Calcium |
Tablet |
II (Paddle) |
75 |
0.05 M Phosphate buffer, pH 6.8 |
900 |
5, 10, 15 and 30 |
2004/01/15 |
| Atorvastatin Calcium |
Suspension |
II (Paddle) |
75 |
0.05 M Phosphate Buffer, pH 6.8 |
900 |
5, 10, 15 and 30 |
2024/05/31 |
| Atorvastatin Calcium/Ezetimibe |
Tablet |
II (Paddle), with option to use a sinker for 20/10 mg strength |
75 |
Phosphate buffer, pH 6.8 with 0.2% w/v Tween 80 |
900 |
5, 10, 15, 20, 30 and 45 |
2014/05/15 |
| Atovaquone |
Tablet |
II (Paddle) |
50 |
40% isopropanol buffered to pH 8.0 with potassium dihydrogen phosphate |
900 |
10, 20, 30, 45, 60 and 90 |
2007/06/18 |
| Atovaquone |
Oral Suspension |
|
|
Develop a dissolution method |
|
|
2009/07/21 |
| Atovaquone/Proguanil HCl |
Tablet |
II (Paddle) with PEAK vessels |
50 |
40% isopropranol buffered to pH 8.0 with potassium dihydrogen phosphate |
900 |
15, 30, 45 and 60 |
2006/08/17 |
| Atropine Sulfate/ Diphenoxylate HCl |
Tablet |
|
|
Develop dissolution method(s) to characterize the dissolution of both components |
|
|
2016/12/22 |
| Auranofin |
Capsule |
|
|
Develop a dissolution method |
|
|
2023/09/15 |
| Avacopan |
Capsule |
II (Paddle) with sinker |
50 |
0.1N HCl |
900 |
10, 20, 30, 45 and 60 |
2023/10/06 |